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The  therapeutic  effect  of  interferon  (IFN)  on chronic  hepatitis  C  and  its  adverse  effects  have  been  well
documented.  Although  the incidence  of  IFN-related  cardiotoxicity  is low,  careful  observation  is necessary
because  of its  possible  fatal  outcome.  We  describe  a 45-year-old  woman  who  suffered  from  sinus  node
dysfunction  after  the  combination  therapy  of  pegylated  IFN-alpha  and  ribavirin  for  chronic  hepatitis
C.  Despite  the  cessation  of  IFN  therapy,  sinus  node  dysfunction  was  not  reversible,  and led  her  to  thenterferon
ick sinus syndrome
hronic hepatitis C
ide effect
implantation  of  permanent  pacemaker.  Physicians  should  therefore  be aware  of the  possibility  of sinus
node  dysfunction  in  patients  receiving  IFN  therapy.
<Learning  objective:  Pegylated  interferon-alpha  has  been  widely  used  to treat hepatitis  C  virus  infection,
which  is  associated  with  a wide  variety  of  adverse  effects.  There  is  a limited  number  of case  reports
regarding  suspected  interferon-induced  cardiotoxicity,  especially  bradyarrhythmia.  We report  a case
with chronic  hepatitis  C who  developed  sick  sinus  syndrome  after  interferon-alpha  therapy.>
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ntroduction
Interferon (IFN)-alpha has been widely used to treat hepatitis
 virus infection and various malignant diseases. A wide variety of
dverse effects of IFN has been reported previously [1]. There is a
imited number of cases in the literature reporting bradyarrhyth-
ia  as an adverse drug reaction to IFN [2,3]. Here, we  report a case
f a 45-year-old woman with chronic hepatitis C virus genotype
b treated with pegylated IFN-alpha (PEG-IFN) and ribavirin who
eveloped sick sinus syndrome.
ase report
A previously healthy 45-year-old woman was referred to a hep-
tologist for the work up for liver injury incidentally spotted at an
nnual health check-up. On physical examination, her blood pres-
ure was 140/80 mmHg, and pulse rate was 90 beats per minute
regular rhythm). There was no jugular venous dilatation, abnor-
al  sounds on chest auscultation, or lower extremity edema. She
ad received a laboratory diagnosis of chronic hepatitis C, genotype
b, and initiated combined therapy using PEG-IFN (80 g/week)
nd ribavirin (600 mg/day) for 48 weeks. Electrocardiogram (ECG)
efore the therapy showed no rhythm abnormality (Fig. 1A).
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Six months after the initiation of PEG-IFN therapy, she suffered
from general malaise and, her ECG revealed sino-atrial (SA) block
(Fig. 1B). Sinus cycle length was gradually decreased to 47/min
during the therapy. She was  diagnosed as having IFN-related
hypothyroidism [thyroid-stimulating hormone (TSH) 41.13 U/ml,
free thyroxine (FT) 4 0.59 ng/dl, FT3 2.98 pg/ml], and treated with
levothyroxine. Even after the normalization of TSH (1.85 U/ml),
her symptoms were not improved and were considered as a psy-
chosomatic side effect, a common side effect of IFN therapy, and no
further examination concerning bradycardia was performed. After
the completion of scheduled PEG-IFN therapy, she consulted our
division for a work up for presyncope and sinus bradycardia.
On physical examination, her consciousness was clear, blood
pressure was 158/97 mmHg, and pulse rate was 57/min (regu-
lar rhythm). There was no jugular venous dilatation, abnormal
sounds on chest auscultation, abnormal abdominal ﬁndings, or
lower extremity edema. Examination of hematological and bio-
chemical parameters revealed no abnormality except subclinical
hypothyroidism (TSH 6.8 U/ml, FT4 1.54 ng/dl, FT3 3.12 pg/ml).
Echocardiography showed preserved cardiac function, and denied
the existence of organic heart disease. We could conﬁrm sinus
bradycardia and frequent occurrences of SA block concomitant
with presyncope on Holter ECG recordings (Fig. 2). The maximum,
minimum, and mean heart rate was  98, 31, and 55/min, and total
heart beats of the day was 74,327. RR intervals more than 3 s were
observed 511 times a day, and reached 3.9 s in the maximum dura-
tion. There was  no atrial ﬁbrillation in Holter recordings repeated
during follow-up.
vier Ltd. All rights reserved.
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Fig. 1. Electrocardiogram before interferon therapy (A) and sino-atrial block found after 6 months (B).
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t
a
pFig. 2. Holter electrocardiographic recordings showinElectrophysiological study performed to evaluate the indica-
ion for pacemaker showed 4.3 s of the secondary pause following
trial overdrive pacing (Fig. 3). Atrio-ventricular conduction was
reserved intact. From these ﬁndings, we made diagnosis of
Fig. 3. Atrial overdrive pacing induced sinus pause and faintness. Even afterrrent sino-atrial block accompanied with presyncope.her illness as sick sinus syndrome, an adverse side effect of
IFN.
After the implantation of a permanent atrial pacemaker,
her symptoms completely disappeared. Six months after the
 the cessation of interferon therapy, sinus node dysfunction remained.
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mplantation, her heart rate was mostly dependent on the pace-
aker even in day time. Her thyroid function was  conﬁrmed to
e euthyroid (TSH 4.23 U/ml, FT4 1.31 ng/dl, FT3 3.38 pg/ml). We
emporarily decreased lower rate of the device to 45 bpm, and
erformed 24 h Holter ECG recording to re-evaluate her sinus node
unction. Almost a quarter (23%) of heart beats were produced by
trial pacing (45/min), that suggested sinus node dysfunction was
rreversible.
iscussion
To the best of our knowledge, this is the ﬁrst report in which a
reviously healthy patient developed irreversible sinus node dys-
unction after IFN therapy. In this case, we could not ﬁnd any
ther cause of sinus node insufﬁciency except IFN therapy, and the
mplantation of permanent cardiac pacemaker was necessary.
IFN therapy has been performed widely to treat chronic hepatitis
 virus infection, which is associated with several side effects, such
s fever, feeling of malaise, headache, blood cell count decrease,
nd depression. A small number of cases of suspected IFN-induced
ardiotoxicity have been reported in the literature. The most
ommon manifestations of cardiotoxicity were tachyarrhythmias,
uch as paroxysmal atrial ﬁbrillation, ventricular tachycardia
nd ﬁbrillation, which were mostly observed in patients with
nderlying heart disease [4]. Teragawa et al. reported that 10 of
95 patients with chronic hepatitis C experienced cardiovascular
dverse effects of IFN [2]. One patient temporarily suffered from
inus bradycardia during IFN therapy, and improved after the ces-
ation of IFN administration. Ribavirin, concomitantly used with
FN, reinforces the effects of IFN on sustained virologic responses.
orriani et al. reported in their randomized, placebo-controlled
rial, that ribavirin did not affect the frequency of adverse events
n IFN therapy [5].
Little is known about the mechanism of IFN-induced sinus node
ysfunction, but Sasaki et al. reported that sensibility of sinus
ode to IFN varies according to the type of IFN or total dose [3].
he combination therapy with IFN-alpha and ribavirin reduces the
iver expression of transforming growth factor beta-1 which pro-
otes liver ﬁbrosis in patients with chronic hepatitis C. On the
ther hand, the expression of matrix metalloproteinase (MMP)  is
ncreased in sinusoidal cells [6]. With respect to the heart, MMP
ubfamilies degrade extracellular matrix proteins and increase car-
iac ﬁbrosis, which leads to myocardial remodeling [7–9]. Previous
tudies showed that ﬁbrosis in and around the sinus node provokes
inus node dysfunction [10–12]. Cardiotoxicity of IFN is potentiated
n pathophysiological conditions such as hypertensive heart dis-
ase [13]. High blood pressure observed in the present case might
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aggravate toxicity and make sinus node dysfunction irreversible.
However, the exact pathogenic mechanisms of irreversible sinus
node dysfunction remain to be elucidated.
The side effects of IFN show various manifestations, which can
result in misdiagnosis of the cause of them. In the administration
of IFN therapy, we should consider the possibility of sick sinus
syndrome and check ECG regularly.
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